RIP1 kinase inhibitor 9

RIP1 kinase inhibitor 9

• UNSPSC Description: RIP1 kinase inhibitor 9 (compound SY-1) is a selective RIP kinase inhibitor. RIP1 kinase inhibitor 9 effectively suppresses the central inflammatory response induced by epilepsy. RIP1 kinase inhibitor 9 inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis in HT-29 cells with an EC50 of 7.04 nM[1].
• Target Antigen: Necroptosis; RIP kinase
• Type: Reference compound
• Related Pathways: Apoptosis
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/rip1-kinase-inhibitor-9.html
• Solubility: 10 mM in DMSO
• Smiles: CN1C([C@H](COC2=CC=CC=C21)NC(C3=CC4=C(NC=C4C5=CC=CC=C5)C=C3)=O)=O
• Molecular Weight: 411.45
• References & Citations: [1]Jiang R, et al. Scaffold hopping derived novel benzoxazepinone receptor-interacting protein kinase 1 (RIP1) inhibitors as anti-necroptosis agents: Anti-inflammatory effect in systemic inflammatory response syndrome (SIRS) and epilepsy. Eur J Med Chem. 2024 Mar 9;269:116304.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported